NCT05489406View on ClinicalTrials.gov

Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

March 24, 2023

Study Completion Date

November 30, 2023

Conditions

Hiv

Interventions

DRUG

DTG DT (6 x 5 mg)

DTG 5mg dispersible tablet

DRUG

F/TAF TOS (3 x 60/7.5 mg)

60/7.5 mg TOS emtricitabine/TAF

Trial Locations (1)

Unknown

RTCCS Radboudumc, Nijmegen

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT05489406 - Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS. | Biotech Hunter | Biotech Hunter